Type 2 inflammation, bronchiectasis and clinical trials: expanding from MAHALE.
B Shoshana Zha, Stephanie A Christenson
原始摘要（英文原文）· Original abstract
MAHALE marks an important advance in bronchiectasis precision medicine as the first large trial to target T2 inflammation. Future considerations should include choice of target, precision phenoendotyping and multidimensional stratification. https://bit.ly/4wlKYYT.